Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
AssigneeThe Regents of the University of California
InventorsArie Belldegrun, Cho-Lea Tso
Life of this patent
Estimating the term…
Abstract
This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
Claims5
A chimeric molecule comprising the sequence of SEQ ID NO:1 from residues 1 to 604.
A composition comprising a chimeric protein comprising the amino acid sequence of SEQ ID NO:1 from position 1 to position 604 thereof and a pharmaceutically acceptable diluent or excipient.
Dependencies are inferred from the claim text.